Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 41.15 CHF -0.48%
Market Cap: 498.8m CHF
Have any thoughts about
Basilea Pharmaceutica AG?
Write Note

Gross Margin
Basilea Pharmaceutica AG

76.6%
Current
82%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
76.6%
=
Gross Profit
114.1m
/
Revenue
149m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CH
Basilea Pharmaceutica AG
SIX:BSLN
498.8m CHF
77%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
318.1B USD
67%
US
Amgen Inc
NASDAQ:AMGN
142.2B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36.2B EUR
89%
Country CH
Market Cap 498.8m CHF
Gross Margin
77%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 318.1B USD
Gross Margin
67%
Country US
Market Cap 142.2B USD
Gross Margin
60%
Country US
Market Cap 117.1B USD
Gross Margin
78%
Country US
Market Cap 105.2B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36.2B EUR
Gross Margin
89%
No Stocks Found

Basilea Pharmaceutica AG
Glance View

Market Cap
498.8m CHF
Industry
Biotechnology

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

BSLN Intrinsic Value
75.14 CHF
Undervaluation 45%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
76.6%
=
Gross Profit
114.1m
/
Revenue
149m
What is the Gross Margin of Basilea Pharmaceutica AG?

Based on Basilea Pharmaceutica AG's most recent financial statements, the company has Gross Margin of 76.6%.